Cannabis Science Professorship
In November 2018, Dr. M-J Milloy was named the University of British Columbia’s first Canopy Growth Professor of Cannabis Science. Under the auspices of this first-of-its-kind professorship, Dr. Milloy will lead clinical trials to explore the use of cannabis for substance use disorders and related conditions. Findings from these clinical trials could help identify ways to better support people with opioid use disorder with cannabis-based therapy.
The professorship was established through funding from Canopy Growth and the Government of British Columbia’s Ministry of Mental Health and Addictions.
The Cannabis Science Symposium is hosted by UBC's Canopy Growth Professor of Cannabis Science.
The inaugural symposium was held on November 25, 2019, and brought together patients and other people with lived experience with researchers, clinicians, and policymakers to discuss and establish a research agenda for cannabis as harm reduction around the theme: "Cannabis and harm reduction: What we know and what we need to learn"
2019 Cannabis Science Symposium program
- Welcom & Keynote
- Session 1: Cannabis and the Overdose Response
- Session 2: Clinical Considerations
- Session 3: Lessions from Lived Experience with Cannabis Use
- Session 4: Clinical Trials in Cannabis
Welcome & Keynote - Dr. Ricky Bluthenthal
Session 1: Cannabis and the Overdose Response
Session 2: Clinical Considerations
Session 3: Lessons from Lived Experience with Cannabis Use
Session 4: Clinical Trials in Cannabis
M-J Milloy, PhD, is a Research Scientist at the British Columbia Centre on Substance Use (BCCSU) and an assistant professor in the Department of Medicine at the University of British Columbia (UBC). On January 1, 2019, he began his appointment as UBC’s inaugural Canopy Growth Professor of Cannabis Science, a position created by arms’ length gifts to the university from Canopy Growth, one of the world’s largest producers of legal cannabis, and the Government of British Columbia’s Ministry of Mental Health and Addictions. At the BCCSU, Dr. Milloy leads observational and experimental research into the public health impact of cannabis regulation and the therapeutic applications of cannabis and cannabinoids, especially for people living with HIV or substance use disorders or at risk of overdose.
Dr. Milloy is the principal investigator of the AIDS Care Cohort to Evaluate exposure to Survival Services (ACCESS) study, a prospective cohort of people living with HIV who use illicit drugs. The ACCESS study is comprised of more than 1,100 individuals living with HIV/AIDS who use illicit drugs. He has authored more than 150 peer-reviewed articles on topics that include the impacts of homelessness and incarceration on HIV treatment outcomes; patterns of non-fatal and fatal overdose; and the impact of Insite, North America’s first medically supervised injecting facility. In 2011, he co-authored a study in The Lancet showing that the establishment of Insite, Vancouver’s first supervised injection facility, preceded a 35% decline in rates of fatal overdose in the vicinity of the low-barrier harm reduction facility compared to 9% in the rest of the City of Vancouver.
Dr. Milloy has won several awards of merit, including the 2011 Bisby Fellowship from the Canadian Institutes of Health Research. Most recently, Natural Green BioMed, Ltd., a private firm applying for a license to produce cannabis, pledged $1-million to UBC to study the therapeutic effects of cannabis and its potential to treat HIV.